Developing a vaccine to trigger protective HIV antibodies
Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies
['FUNDING_OTHER'] · DUKE UNIVERSITY · NIH-10547799
This study is testing a new vaccine that aims to help your body produce certain antibodies to fight HIV-1, making it easier to prevent the virus from spreading, and it's designed for anyone interested in better ways to protect against HIV.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10547799 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a vaccine that can effectively induce non-neutralizing antibodies (NNAbs) against HIV-1, which are easier to produce than broadly neutralizing antibodies. The approach involves using messenger RNA immunogens to stimulate the immune system to generate these antibodies, which may help in preventing HIV transmission. The study aims to build on previous vaccine trials and improve the design of immunogens to enhance the immune response. By exploring different combinations of envelope proteins, the research seeks to find the most effective way to induce protective antibody responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of HIV infection who are seeking preventive measures.
Not a fit: Patients who are already living with HIV or those who have contraindications to vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that provides better protection against the virus.
How similar studies have performed: Previous vaccine trials have shown some success in inducing protective antibodies, but this approach aims to refine and improve upon those methods.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAYNES, BARTON F. — DUKE UNIVERSITY
- Study coordinator: HAYNES, BARTON F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immunodeficiency Syndrome Virus